Sun Pharma, subsidiary enter settlements in Modafinil antitrust litigation pending in US district court

In a regulatory filing, Sun Pharma said 'the settlements extend to all claims brought by the Direct Purchaser Plaintiffs'.

Press Trust of India November 27, 2018 12:32:28 IST
Sun Pharma, subsidiary enter settlements in Modafinil antitrust litigation pending in US district court

New Delhi: Drug major Sun Pharmaceutical Industries Monday said the company along with its subsidiary has entered into settlements with certain plaintiffs in the Modafinil antitrust litigation pending in the US District Court for the Eastern District of Pennsylvania. The company, however, did not disclose the details of the settlement, saying the terms are confidential.

Sun Pharma subsidiary enter settlements in Modafinil antitrust litigation pending in US district court

Representational image. Reuters

In a regulatory filing, Sun Pharma said "the settlements extend to all claims brought by the Direct Purchaser Plaintiffs".

The company "and one of its wholly-owned subsidiaries have entered into settlements with certain plaintiffs in the 'In re Modafinil Antitrust Litigation' matter pending in the United States District Court for the Eastern District of Pennsylvania," Sun Pharma said in a filing to the BSE. Earlier in a regulatory filing on the quarterly results on 13 November, 2018, the pharma major had reported a consolidated net loss of Rs 218.82 crore for the July-September quarter on account of a Rs 1,214-crore provision for the settlement of the Modafinil antitrust case in the US.

"After accounting for the provision of Rs 1,214 crore for the estimated settlement amount payable to all the remaining plaintiffs related to the Modafinil antitrust litigation in the US, the net loss for the quarter was at Rs 219 crore," Sun Pharma had said. Modafinil is a wakefulness-promoting drug for oral administration.

Updated Date:

also read

Going private: Sun Pharma wins over Taro with higher offer
Business

Going private: Sun Pharma wins over Taro with higher offer

Upon completion of the merger, Taro will become a privately held company, will be wholly owned by affiliates of Sun Pharma, and its ordinary shares will no longer be traded on the New York Stock Exchange.

Sebi fines Sun Pharma Advanced Research's promoter entity Rs 3 lakh
Corporate

Sebi fines Sun Pharma Advanced Research's promoter entity Rs 3 lakh

The Securities and Exchange Board of India (Sebi), in its order, has imposed a penalty on Virtuous Share Investments "which will be commensurate with the violation committed by it".<br />

$4 bn Sun Pharma-Ranbaxy merger gets green signal from BSE, NSE
Corporate

$4 bn Sun Pharma-Ranbaxy merger gets green signal from BSE, NSE

The U$4-billion merger of Ranbaxy Labs with Sun Pharmaceutical has got clearance from the two leading stock exchanges -- BSE and NSE.